Mission
Delivering a gift from cancer survivor to patients
Vision
An enterprise leading next-generation of targeted therapeutics
History
2018
First Study of Survivor’s Antibody from TNBC
2021
Patented the first antibody from TNBC survivor SS001
2022
Patented the first survivor’s Ab SS001 from TNBC
2023
Discovery of novel Ab from colon cancer survivor, in collaboation with AMC
2024
Awarded 1st phase of Deep Science National start-up grant
2025
Awarded 2nd phase of the Deep Science National start-up grant
Founded Survivant Biologics, Announced 1st CEO Kiwsu Park
Patented CharisMab platform internationally
Greetings from CEO
Please join us for the innovative adventure to provide hope to cancer patients
Survivant Biologics provide an innovative solution to current cancer therapeutics market, based on the value of cancer survivors
Our company has been established on a simple question of ” Do cancer survivors keep something in their body that enable them to eradicate cancer?”
This question led us to discover and develop a platform technology called CharisMab, which will open a new revenue for the discovery of targeted cancer therapeutics.
Survivant Biologics will propel this platform technology to find and prove the value of survivor’s antitumor antibody, that has been drawing attention from many investors and potential collaborators. We will not only develop the survivor’s antibody per se, but also build a strategic consortium to expand its potential to various modalities of targeted therapy
Please join us to this exciting journey that ultimately make our dream of curing cancer come true.
Thank you very much,
Kiwis Park, CEO
Directors
Suhwan Chang, Founder (CTO)
Expert in cancer therapeutics and preclinical model
Professor,
University of Ulsan, College of Medicine, Asan Medical Center
Ph.D. from KAIST, Korea
Postdoc in Florida State Univ.
Research Fellow in NCI, NIH
Vice President in AMC-SCIENCES
SAB in various bioventures
Kiwis Park, CEO
Expert in License and patent in biologics
Patent Lawyer
Board of Director in Celltrion
Expert in global patent strategy
Expert in license with global pharma
Core Members
Hyunnam Cho, Director in R&D
Expert in antibody screening and engineering
Abclone
AMC-SCIENCES
Ph.D. in Kyoto University
Taegyun Chung, Board of Director
Business development and investment
Partner patent lawyer, BLT Inc.
CSO/CIPO, SSen Stone Inc.
SAB (Scientific Advisory Board)
Kyung Kon Kim, Ph.D.
Expert in clinical proteomics
University of Ulsan
Asan Medical Center
Proteomics based on LC-MS/MS
Expert in Biomarker discovery and development
Hyori Kim, Principal Investigator
Expert in therapeutic antibody development
In Ja Park, M.D., Ph.D.
Expert in colon cancer
Professor in University of Ulsan, College of Medicine
Director of colon cancer division in Asan Medical Center
Clinical research on patient derived unmet need
Sae Byul Lee, M.D., Ph.D.
Breast cancer expert
Professor in University of Ulsan, College of Medicine
Collaborator in the foundation project of screening of survivor’s antibody
Shin Hwa Lee, M.D., Ph.D.
Expert in ovarian cancer clinical research
Professor in University of Ulsan, College of Medicine
Clinical research in women’s cancer, Prognosis, Biomarker study
Yung Sup Kim, Ph.D.
Expert in genome editing by CRISPR
Associate Professor in Digital Medicine in Asan Medical Center
Samsung Electronics Research Center